Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

103.00p
   
  • Change Today:
      2.60p
  • 52 Week High: 110.00
  • 52 Week Low: 75.00
  • Currency: UK Pounds
  • Shares Issued: 538.04m
  • Volume: 864,074
  • Market Cap: £554.19m
  • RiskGrade: 119
  • Beta: 0.20

Alliance Pharma trades strongly through first half

By Josh White

Date: Tuesday 20 Jul 2021

LONDON (ShareCast) - (Sharecast News) - Healthcare company Alliance Pharma updated the market on its first half on Tuesday, reporting that it had traded "strongly", with see-through revenue rising 24% year-on-year to £80.9m, or 28% on a constant currency basis.
The AIM-traded firm said that excluding 'Amberen', which was acquired in December, like-for-like see-through revenue totalled £71.4m for the six months ended 30 June, which was 9% higher than the first half of 2020, or 12% at constant exchange rates.

Based on trading in the year-to-date, its board said it was expecting underlying profit before tax for the full year to be in line with market expectations.

It said its consumer healthcare brands were performing strongly, with total divisional revenues up 30% to £56.8m, and like-for-like revenues, excluding Amberen, ahead 8% to £47.3m.

'Kelo-cote' delivered another strong performance, with revenues up 54% to £21.9m, while Amberen continued to trade in line with its pre-acquisition expectations, generating revenues of £9.5m, making for a constant currency increase of 10%.

'Nizoral' revenues were 8% lower than the same period last year at £9.0m, or 7% weaker on a constant currency basis, primarily due to the phasing of distributor orders.

Alliance reported an uplift in its prescription medicines business in the period, with revenues increasing 12% to £24.1m, as some of the negative impact of Covid-19 on the delivery of routine treatments eased.

Free cash flow for the period totalled £6.5m, down from £10.5m a year earlier, with the board putting the reduction down to the expected reversal of the favourable working capital movements in the fourth quarter of 2020, and the timing of sales within the period.

Net debt narrowed by £2.7m to £106.7m as at 30 June, as group leverage reduced to 2.21x at period end, from 2.43x at the end of December.

Its directors said they still expected that to fall below 2x by the end of the year.

"Our consumer healthcare business continues to perform well - Kelo-cote in particular enjoyed a very strong first half," said chief executive officer Peter Butterfield.

"We were pleased with the first half performance from Amberen, and the integration of the brand into our US-based operations is now complete.

"We expect the group's strong performance will continue throughout the second half, and anticipate this will have a positive impact on cash generation and our ability to further deleverage by the year-end."

At 0909 BST, shares in Alliance Pharma were up 1.81% at 101.2p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 103.00p
Change Today 2.60p
% Change 2.59 %
52 Week High 110.00
52 Week Low 75.00
Volume 864,074
Shares Issued 538.04m
Market Cap £554.19m
Beta 0.20
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
85.8% below the market average85.8% below the market average85.8% below the market average85.8% below the market average85.8% below the market average
28.00% above the sector average28.00% above the sector average28.00% above the sector average28.00% above the sector average28.00% above the sector average
Price Trend
59.50% above the market average59.50% above the market average59.50% above the market average59.50% above the market average59.50% above the market average
30.00% above the sector average30.00% above the sector average30.00% above the sector average30.00% above the sector average30.00% above the sector average
Income
50% below the market average50% below the market average50% below the market average50% below the market average50% below the market average
27.27% above the sector average27.27% above the sector average27.27% above the sector average27.27% above the sector average27.27% above the sector average
Growth
13.07% below the market average13.07% below the market average13.07% below the market average13.07% below the market average13.07% below the market average
94.12% below the sector average94.12% below the sector average94.12% below the sector average94.12% below the sector average94.12% below the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 3
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Interim Final
Ex-Div 16-Dec-21 10-Jun-21
Paid 07-Jan-22 08-Jul-21
Amount 0.56p 1.07p

Trades for 03-Dec-2021

Time Volume / Share Price
16:37 150,000 @ 102.43p
16:37 150,000 @ 102.43p
16:40 16,675 @ 102.43p
16:35 156,651 @ 103.00p
16:29 18 @ 101.80p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin

Top of Page